Circassia Share Discussion Threads

[neilyb675] 09/4/2020 08:06

22.35 - 23.00 (GBX) at 08:06:03
on Market (LSE)

[neilyb675] 09/4/2020 08:06

Market likes it

[neilyb675] 09/4/2020 08:03

Lonnnnnnnnng auction

[babbler] 09/4/2020 08:01

No it's not. Must be a reason. Now debt free and have a good product left

[basem1] 09/4/2020 07:59

It's negative overall imo.

[bjfanc] 09/4/2020 07:56

Looks like those COPD products were causing large losses and they don't have the resources to spend to take on the big boys in this market.

[rbonnier] 09/4/2020 07:55

The company wasnt pleased to announce .I think if it's for all of it its negative.

[pro_s2009] 09/4/2020 07:53

Seems to be only the US rights.

As soon as I get the Broker update note I will post it on here.

[basem1] 09/4/2020 07:50

If it is only the American rights then it's not so bad. CIR retain rights for the rest of the world ?

[mad foetus] 09/4/2020 07:49

Hard to judge, we are selling a lot of jam tomorrow in return for $150m. I suspect in current environment that has to be a positive.

[ayl30] 09/4/2020 07:41

Looks potentially good news to me

[pro_s2009] 09/4/2020 07:32

There is a lot to digest in the whole release.....only a portion copied above.

[neilyb675] 09/4/2020 07:26

Wasn't expecting that.

So all debt gone.

AZN retain 19% holding in CIR.

What does share price do in reaction ?

[pro_s2009] 09/4/2020 07:06

Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest

Oxford, UK - 9 April 2020 Circassia Pharmaceuticals plc, ("Circassia" or "the Company"; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to Tudorza(R) and Duaklir(R) and transfer the assets to AstraZeneca (the Transaction).

On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza(R) and Duaklir(R) together with certain ancillary rights and assets, from Circassia the consideration for which shall be equal to, and shall be satisfied by way of set-off against, the entirety of the loan amount outstanding from the Company to AstraZeneca, together with accrued interest owed by the Company to AstraZeneca, as at the date of completion of the Transaction (being approximately US$149.9 million as at the date of announcement) AstraZeneca will retain its 18.9% shareholding in the Company. Subject to receipt of necessary approvals, it is anticipated that the Transaction will complete in no longer than three months.

The proposed Transaction will constitute a fundamental change of business of Circassia under Rule 15 of the AIM Rules for Companies and is therefore conditional on, inter alia, the passing of an ordinary resolution to approve the Transaction at the General Meeting, a circular convening the General Meeting is expected to be posted to Shareholders shortly. In addition, the Transaction is considered to constitute a related party transaction under Rule 13 of the AIM Rules for Companies.

On completion of the Transaction, Circassia proposes to change its name to Circassia Group plc, subject to the passing of a special resolution to approve the Company's change of name at the General Meeting.

Ian Johnson, Circassia's Executive Chairman, said: "As a Board and Management team, we conducted a strategic review of our business and its prospects, concluding that it would be in the best interests of both patients and our shareholders for us to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited for the U.S. commercial rights to Tudorza(R) and Duaklir(R).

As we look to move forwards with a primary focus on our Niox(R) respiratory diagnostic platform, we are confident in our ability to drive long-term growth. Upon completion, this transaction will transform Circassia into a debt-free business with a strong revenue-generating business, with which we have the potential to expand into new territories and a commercial infrastructure that can in the medium term be further leveraged through broadening its range of products. This fundamental change in the business will place us in a strong position to deliver improved shareholder value."

[pro_s2009] 09/4/2020 07:05

Big news today...........

All debt gone.

[pro_s2009] 09/4/2020 02:50

CIP’s portfolio also includes valuable stakes worth a total of £4.5m in Orthofix Medical (US:OFIX), an US$500m market capitalisation Nasdaq quoted medical devices company, and Aim-traded Circassia Pharmaceuticals (CIR), a cash-rich speciality biopharmaceutical company focused on allergy and respiratory diseases. I can see upside to both investments, and several other of CIP’s holdings, too. The decision to widen the investment manager’s sector remit is sensible in light of the value opportunities across the whole market. Buy.

[chutes01] 08/4/2020 19:55

great chart

[mdchand] 08/4/2020 18:23

ascending triangle. poised to break out but seems to hit resistance at 18p. Wonder if we have a persistent seller. Let's see if we can break and hold above 18p tommorrow.

[chutes01] 08/4/2020 17:19

bid likely

[gemlotte55] 08/4/2020 17:05

Ayl30
Are you able to post the snippet please

[minja19] 08/4/2020 16:10

someone explain to me the multiple small trades.
I need to learn something.

[pro_s2009] 08/4/2020 12:48

Thats why the sudden spike up.

[pro_s2009] 08/4/2020 12:48

Appears that Simon Thompson of the Investors Chronicle has tipper CIR.

[ayl30] 08/4/2020 12:47

Tipped by Simon Thompson on IC website today